Oncimmune: Platform biomarker company with proprietary EarlyCDT® technology. Developing and commercialising autoantibody (AAb) tests that can enable detection 4 years or more before standard clinical diagnosis, and stratify patients into response to treatment. Two marketed products, EarlyCDT®-Lung launched in 2012 and EarlyCDT®-Liver launched in 2018, and a broad advanced pipeline of early cancer detection tests, incl. prostate, breast and ovarian. Global presence, incl. US (155m US lives covered; 156,000 EarlyCDT®-Lung tests sold since launch) and China. Leading immunogenic library; broad and comprehensive patent portfolio.
Healthcare/Medical Diagnostics & Research
Based in...
Europe, United Kingdom
Disease Space
Diagnostics, Immuno-Oncology, Oncology
Europe, Public
Market Cap
184 Shepherd’s Bush Road
London, W6
United Kingdom

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

European Biotech Investor Day 2019

New York City, August 1, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.